Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19

Siltuximab - A monoclonal antibody against the interleukin-6 receptor is not an ideal option for management of COVID-19

The sudden outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which emerged in Wuhan city, China, has resulted in a global pandemic, posing a major health concern worldwide. Despite multiple therapeutic interventions, no treatment has yet proven effective in treating COVID-19....

Full description

Bibliographic Details
Main Authors: I Jerlin Michelle, S A Shevaani, Kiran Kumar Rathinam, Justin Jacob Abraham, Muhasaparur Ganesan Rajanandh, Thangavel Mahalingam Vijayakumar
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Current Medicine Research and Practice
Subjects:
covid-19
cytokine release syndrome
interleukin-6
monoclonal antibody
siltuximab
Online Access:http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=3;spage=121;epage=124;aulast=Michelle

Internet

http://www.cmrpjournal.org/article.asp?issn=2352-0817;year=2021;volume=11;issue=3;spage=121;epage=124;aulast=Michelle

Similar Items